Even as Biogen execs scrambled to defend Aduhelm and paint a rosy future the drug promises to unleash, R&D chief Al Sandrock reassured analysts during a recent earnings call that his team had more Alzheimer’s tricks.

In particular, he emphasized his belief in tau as a potential target — even though gosuranemab, the lead anti-tau antibody, had just failed a Phase II study.

“Whereas we have discontinued the BIIB092 program, we are continuing the development of BIIB080, our antisense oligonucleotide, which aims to reduce the production of all forms of tau both intra and extracellular,” he said.